drugset / Trial / NCT06560333

iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)

NCT06560333

Phase 3 Withdrawn Eurofarma Laboratorios S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.

Timeline

Start
2026-11-30
Primary completion
2027-04-30
Completion
2029-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Forxiga Unknown 10 mg Oral
Comparator Sitagliptin Small molecule 100 mg Oral
Comparator Metformin Small molecule 1000 mg Oral